샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784877

세계의 인공 임신중절약 시장

Abortion Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 280 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 인공 임신중절약 시장은 2030년까지 379억 달러에 이를 전망

2024년에 255억 달러로 추정되는 인공 임신중절약 세계 시장은 분석 기간인 2024-2030년 CAGR 6.9%로 성장하여 2030년에는 379억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Mifepristone은 CAGR 8.7%를 나타내고, 분석 기간 종료시에는 65억 달러에 이를 것으로 예측됩니다. Misoprostol 부문의 성장률은 분석 기간중 CAGR 7.2%로 추정됩니다.

미국 시장은 69억 달러로 추정, 중국은 CAGR 10.9%로 성장 예측

미국의 인공 임신중절약시장은 2024년에 69억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 80억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 10.9%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.3%와 6.7%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.5%를 보일 전망입니다.

세계의 인공 임신중절약 시장 - 주요 동향과 촉진요인 정리

인공 임신중절약 시장의 성장을 주도하는 요인은?

약물 낙태에 대한 안전하고 효과적인 대안에 대한 수요 증가가 인공 임신중절약 시장의 주요 촉진요인입니다. 생식 건강과 권리에 대한 인식이 높아짐에 따라 여성들은 보다 덜 침습적이고 사적인 수술적 낙태의 대안을 원하고 있습니다. 미페프리스톤이나 미소프로스톨과 같은 약물에 의해 촉진되는 약물 낙태는 임신을 조기에 종료할 수 있는 안전하고 편리한 옵션을 제공하며, 전 세계적으로 이러한 제품의 채택에 박차를 가하고 있습니다.

규제 상황의 발전도 시장 성장에 기여하고 있습니다. 특히 생식권(성 및 생식에 관한 권리)에 대한 전 세계적인 논의에 따라 많은 국가들이 법과 가이드라인을 개정하고 낙태약에 대한 접근성을 확대하기 위해 노력하고 있습니다. 이러한 변화로 인해 낙태약은 약국, 진료소, 심지어 원격의료 플랫폼에서도 이용할 수 있게 되어 도시, 농촌, 낙후된 지역의 여성들이 보다 쉽게 접근할 수 있게 되었습니다. 이러한 변화는 수술적 낙태 서비스가 제한적이거나 이용할 수 없는 지역에서는 특히 중요합니다.

원격 의료의 역할 증가는 시장 성장을 가속하는 또 다른 중요한 요인입니다. 낙태 의료에 원격 의료 서비스가 통합되면서 여성들은 원격으로 의료 전문가와 상담하고 낙태약을 편리하게 이용할 수 있게 되었습니다. 이러한 추세는 코로나19 팬데믹 기간 동안 더욱 탄력을 받았으며, 의료 제공업체와 환자가 모두 디지털 솔루션을 수용함에 따라 계속 번창하고 있습니다. 원격의료가 제공하는 편의성, 프라이버시, 접근성은 낙태약의 보급을 촉진하고 전 세계로 확산되고 있습니다.

기술 발전은 인공 임신중절약 시장을 어떻게 형성하고 있는가?

의약품 연구의 발전은 약효와 안전성 프로파일을 개선함으로써 인공 임신중절약 시장을 크게 형성하고 있습니다. 약물 제형 및 전달 메커니즘의 혁신은 더 높은 성공률, 더 적은 부작용, 환자의 회복 시간 단축을 보장합니다. 예를 들어, 미페프리스톤과 미소프로스톨의 조합이 개선되어 출혈과 통증을 보다 효과적으로 조절할 수 있게 되었습니다. 이러한 발전으로 의료진과 환자의 약물 낙태 방법에 대한 신뢰가 높아지면서 의료진과 환자의 낙태 방법에 대한 신뢰가 높아지고 있습니다.

디지털 헬스 기술 또한 낙태약의 처방과 유통 방식을 바꾸고 있습니다. 텔레헬스 플랫폼과 모바일 헬스 앱은 여성들이 신중하고 편리하게 낙태 치료를 받을 수 있도록 돕고 있습니다. 이 플랫폼을 통해 환자는 허가받은 의료 전문가와 상담하고, 처방전을 받아 낙태약을 집으로 직접 배달받을 수 있습니다. 낙태 의료와 디지털 도구의 통합은 특히 원격지나 낙후된 지역에서 접근성을 개선하고 의료 가이드라인을 준수할 수 있도록 돕고 있습니다.

또한, 환자와 의료 서비스 제공업체 모두를 위한 교육 및 지원 도구의 개발이 시장을 강화하고 있습니다. 모바일 앱과 온라인 플랫폼은 낙태약 사용에 대한 단계별 지침을 제공하고, 진행 상황을 모니터링하고, 부작용을 관리하는 데 사용됩니다. 이러한 리소스는 여성이 과정 전반에 걸쳐 신뢰할 수 있는 정보와 지원을 이용할 수 있도록 하여 결과와 환자 만족도를 향상시킵니다. 디지털 기술이 계속 발전함에 따라 낙태 의료에 대한 접근성을 확대하고 그 질을 향상시키는 데 있어 디지털 기술의 역할은 더욱 커질 것으로 예측됩니다.

낙태약이 여성과 의료시스템에 미치는 이점은 무엇인가?

여성에게 낙태약은 안전하고, 프라이버시를 보호하며, 비침습적인 조기 임신중절 옵션을 제공합니다. 약물 낙태는 특히 의료 인프라가 부족한 지역에서는 일반적으로 수술보다 비용이 적게 들고 접근이 용이한 방법입니다. 낙태약을 통해 여성은 자신의 생식 건강을 통제하고 안전하고 편안한 환경에서 결정을 내릴 수 있습니다. 또한, 약물 낙태는 회복 시간이 짧고 합병증 위험이 낮기 때문에 많은 여성들이 선호하는 선택입니다.

낙태약은 또한 수술이나 병원 치료의 필요성을 줄여 의료 시스템의 부담을 줄여줍니다. 여성이 집이나 외래에서 조기에 낙태를 할 수 있도록 함으로써, 약물 낙태는 다른 중요한 의료 수요에 자원을 투입할 수 있게 합니다. 이는 의료시설과 인력이 과잉인 경우가 많은 저자원 환경에서 특히 유용합니다. 낙태약을 원격의료 플랫폼과 통합함으로써 대면 진료를 줄이고, 진료의 효율성을 높일 수 있습니다.

또한, 낙태약은 전 세계 생식권 증진에 있어 중요한 역할을 하고 있습니다. 안전하고 효과적인 낙태 시술에 대한 접근성을 향상시킴으로써 여성의 건강과 생명에 심각한 위험을 초래하는 위험한 낙태 행위의 확산을 줄일 수 있습니다. 또한, 낙태약의 가용성은 여성이 생식 선택에 대한 자율성을 행사할 수 있도록 함으로써 성 평등에 기여하고, 보다 광범위한 사회적, 경제적 이익을 뒷받침합니다.

인공 임신중절약 시장 성장 촉진요인은 무엇인가?

생식 건강(성 및 생식 건강 및 권리)에 대한 인식이 높아지면서 인공 임신중절약 시장의 주요 촉진요인으로 작용하고 있습니다. 여성들이 임신 관리 옵션에 대한 지식이 높아지면서 안전하고 효과적인 낙태약에 대한 수요가 증가하고 있습니다. 이러한 추세는 생식 보건 의료에 대한 접근성을 높이고 낙태 치료의 장벽을 없애기 위한 전 세계적인 옹호 활동에 의해 더욱 강화되고 있습니다.

규제 변화와 정책적 지원도 시장을 견인하고 있습니다. 정부와 의료 기관은 법 개정, 유통 경로 확대, 약물 낙태를 공중 보건 시스템에 포함시킴으로써 낙태 약품에 대한 접근성을 개선하기 위해 노력하고 있습니다. 이러한 노력은 낙태 관련 법률이 제한적이거나 수술 서비스에 대한 접근성이 제한된 지역에서 특히 큰 영향을 미치며, 더 많은 여성들이 안전하고 효과적인 치료의 혜택을 누릴 수 있도록 돕습니다.

마지막으로, 원격의료의 보급이 시장을 가속화하고 있습니다. 원격 진료 및 처방 서비스를 가능하게 함으로써 원격 의료 플랫폼은 낙태약에 대한 접근성을 확대하고, 그 과정을 여성에게 더 편리하고 사적인 것으로 만들고 있습니다. 이러한 촉진요인은 약물 제제 및 약물 전달 시스템의 발전과 함께 향후 몇 년 동안 인공 임신중절약 시장을 지속적인 성장과 혁신의 길로 이끌 것입니다.

부문

약제 클래스(Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost, 기타 약제 클래스별), 유통 채널(병원 약국 유통 채널, 소매 약국 유통 채널, 온라인 약국 유통 채널)

조사 대상 기업 예

  • Cipla Ltd
  • Corcept Therapeutics, Incorporated
  • Dr. Reddy's Laboratories, Inc
  • Exelgyn
  • GenBioPro
  • Kabir Lifesciences
  • Lupin Limited
  • Pfizer Inc.
  • Sao Kim Pharmaceutical JSC
  • Somacare
  • Synokem Pharmaceuticals Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals USA, Inc.
  • Torrent Pharmaceuticals Ltd
  • VIVAN Life Sciences Pvt. Limited.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.12

Global Abortion Drugs Market to Reach US$37.9 Billion by 2030

The global market for Abortion Drugs estimated at US$25.5 Billion in the year 2024, is expected to reach US$37.9 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Mifepristone, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.5 Billion by the end of the analysis period. Growth in the Misoprostol segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.9 Billion While China is Forecast to Grow at 10.9% CAGR

The Abortion Drugs market in the U.S. is estimated at US$6.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.0 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Abortion Drugs Market - Key Trends & Drivers Summarized

What Is Driving the Growth of the Abortion Drugs Market?

The rising demand for safe and effective options for medical abortion is a major driver of the Abortion Drugs market. With increasing awareness about reproductive health and rights, women are seeking alternatives to surgical abortion methods that are less invasive and more private. Medical abortion, facilitated by drugs such as mifepristone and misoprostol, provides a safe and convenient option for terminating early pregnancies, fueling the adoption of these products worldwide.

Evolving regulatory landscapes are also contributing to market growth. Many countries are working to expand access to abortion drugs by revising laws and guidelines, especially in the wake of global discussions around reproductive rights. These changes are enabling the availability of abortion drugs in pharmacies, clinics, and even via telemedicine platforms, ensuring greater accessibility for women in urban, rural, and underserved regions. This shift is particularly significant in regions where surgical abortion services are limited or unavailable.

The increasing role of telemedicine is another significant factor driving market growth. The integration of telehealth services with abortion care has enabled women to consult healthcare professionals remotely and access abortion drugs conveniently. This trend gained momentum during the COVID-19 pandemic and continues to thrive as healthcare providers and patients alike embrace digital solutions. The convenience, privacy, and accessibility offered by telemedicine are enhancing the adoption of abortion drugs and expanding their reach globally.

How Are Technological Advancements Shaping the Abortion Drugs Market?

Advancements in pharmaceutical research are significantly shaping the Abortion Drugs market by improving drug efficacy and safety profiles. Innovations in drug formulations and delivery mechanisms are ensuring higher success rates, fewer side effects, and shorter recovery times for patients. For instance, improved combinations of mifepristone and misoprostol are providing more effective outcomes, with better control of bleeding and pain. These advancements are increasing the confidence of healthcare providers and patients in using medical abortion methods.

Digital health technologies are also transforming how abortion drugs are prescribed and distributed. Telehealth platforms and mobile health apps are enabling women to access abortion care discreetly and conveniently. Through these platforms, patients can consult with licensed healthcare professionals, receive prescriptions, and have abortion drugs delivered directly to their homes. The integration of digital tools with medical abortion care is improving access and ensuring compliance with medical guidelines, especially in remote and underserved regions.

Additionally, the development of educational and support tools for both patients and healthcare providers is enhancing the market. Mobile apps and online platforms are being used to provide step-by-step guidance on the use of abortion drugs, monitor progress, and manage side effects. These resources ensure that women have access to reliable information and support throughout the process, improving outcomes and patient satisfaction. As digital technologies continue to evolve, they are expected to play an even greater role in expanding access to and improving the quality of abortion care.

What Are the Benefits of Abortion Drugs for Women and Healthcare Systems?

For women, abortion drugs provide a safe, private, and non-invasive option for terminating early pregnancies. Medical abortion is typically less costly and more accessible than surgical procedures, especially in regions with limited healthcare infrastructure. The availability of abortion drugs empowers women to take control of their reproductive health and make decisions in a setting that feels safe and comfortable. Additionally, the shorter recovery times and lower risk of complications associated with medical abortion make it a preferred choice for many women.

Abortion drugs also reduce the burden on healthcare systems by decreasing the need for surgical procedures and hospital-based care. By enabling women to manage early abortions at home or in outpatient settings, medical abortion frees up resources for other critical healthcare needs. This is particularly beneficial in low-resource settings where healthcare facilities and personnel are often overstretched. The integration of abortion drugs with telemedicine platforms further enhances efficiency by reducing in-person visits and streamlining care delivery.

Moreover, abortion drugs play a critical role in advancing global reproductive rights. By increasing access to safe and effective abortion care, these drugs help reduce the prevalence of unsafe abortion practices that pose significant risks to women’s health and lives. The availability of abortion drugs also contributes to gender equality by ensuring that women can exercise autonomy over their reproductive choices, supporting broader societal and economic benefits.

What Are the Key Market Drivers for Abortion Drugs?

The increasing awareness of reproductive health and rights is a major driver of the Abortion Drugs market. As women become more informed about their options for managing pregnancies, the demand for safe and effective abortion drugs is growing. This trend is further supported by global advocacy efforts to promote access to reproductive healthcare and eliminate barriers to abortion care.

Regulatory changes and policy support are also driving the market. Governments and healthcare organizations are working to improve access to abortion drugs by revising laws, expanding distribution channels, and integrating medical abortion into public health systems. These efforts are particularly impactful in regions with restrictive abortion laws or limited access to surgical services, enabling more women to benefit from safe and effective care.

Finally, the growing adoption of telemedicine is accelerating the market. By enabling remote consultations and prescription services, telehealth platforms are expanding access to abortion drugs and making the process more convenient and private for women. Combined with advancements in drug formulations and delivery systems, these drivers are positioning the Abortion Drugs market for sustained growth and innovation in the coming years.

SCOPE OF STUDY:

The report analyzes the Abortion Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost, Other Drug Classes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Cipla Ltd
  • Corcept Therapeutics, Incorporated
  • Dr. Reddy's Laboratories, Inc
  • Exelgyn
  • GenBioPro
  • Kabir Lifesciences
  • Lupin Limited
  • Pfizer Inc.
  • Sao Kim Pharmaceutical JSC
  • Somacare
  • Synokem Pharmaceuticals Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals USA, Inc.
  • Torrent Pharmaceuticals Ltd
  • VIVAN Life Sciences Pvt. Limited.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Abortion Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Non-Surgical Termination Methods Throws the Spotlight on Medical Abortion Drugs
    • Shifting Socio-Political Landscapes and Reproductive Rights Debates Propel Market Visibility and Access Challenges
    • Growing Preference for Privacy and Convenience Expands the Addressable Market for Home-Use Abortion Pills
    • Increased Availability Through Telemedicine Strengthens the Business Case for Digitally Accessible Abortion Drug Services
    • Global Public Health Advocacy for Reproductive Autonomy Drives Policy Reforms and Market Expansion
    • Technological Advancements in Drug Formulation and Dosage Optimization Drive Product Differentiation
    • Rising Incidence of Unintended Pregnancies in Developing Regions Fuels Demand for Cost-Effective Medical Termination Options
    • NGO and Government Support for Women's Health Initiatives Enhances Access in Underserved Geographies
    • Cross-Border E-Commerce and Mail-Order Services Generate New Distribution Channels and Compliance Challenges
    • Integration of Abortion Drugs in Family Planning Programs Drives Market Penetration in Public Health Systems
    • Backlash Against Legal Restrictions Creates Parallel Demand Through Informal and Grey Market Channels
    • Pharmaceutical Pipeline Innovation and Generic Drug Manufacturing Expand Affordability and Availability
    • Risk Management, Safety Monitoring, and Adverse Event Surveillance Systems Strengthen Trust in Medical Abortion Protocols
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Abortion Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Abortion Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mifepristone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Mifepristone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Mifepristone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Misoprostol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Misoprostol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Misoprostol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pitocin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pitocin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Pitocin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hemabate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hemabate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hemabate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Carboprost by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Carboprost by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Carboprost by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Abortion Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Abortion Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Abortion Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Abortion Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Abortion Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Abortion Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Abortion Drugs by Drug Class - Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Abortion Drugs by Drug Class - Percentage Breakdown of Value Sales for Mifepristone, Misoprostol, Pitocin, Hemabate, Carboprost and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Abortion Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Abortion Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제